High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end‐stage liver disease

K. Rajender Reddy, Jacqueline G. O'Leary, Patrick S. Kamath, Michael B. Fallon, Scott W. Biggins, Florence Wong, Heather M. Patton, Guadalupe Garcia‐Tsao, Ram M. Subramanian, Leroy R. Thacker, Jasmohan S. Bajaj, for the North American Consortium for the Study of End‐Stage Liver Disease – 4 April 2015 – Because Model for End‐Stage Liver Disease (MELD) scores at the time of liver transplantation (LT) increase nationwide, patients are at an increased risk for delisting by becoming too sick or dying while awaiting transplantation.

The camKK2/camKIV relay is an essential regulator of hepatic cancer

Fumin Lin, Kathrina L. Marcelo, Kimal Rajapakshe, Cristian Coarfa, Adam Dean, Nathaniel Wilganowski, Holly Robinson, Eva Sevick, Karl‐Dimiter Bissig, Lauren C. Goldie, Anthony R. Means, Brian York – 4 April 2015 – Hepatic cancer is one of the most lethal cancers worldwide. Here, we report that the expression of Ca2+/calmodulin‐dependent protein kinase kinase 2 (CaMKK2) is significantly up‐regulated in hepatocellular carcinoma (HCC) and negatively correlated with HCC patient survival.

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

K. Rajender Reddy, Marc Bourlière, Mark Sulkowski, Masao Omata, Stefan Zeuzem, Jordan J. Feld, Eric Lawitz, Patrick Marcellin, Tania M. Welzel, Robert Hyland, Xiao Ding, Jenny Yang, Steven Knox, Phillip Pang, Hadas Dvory‐Sobol, G. Mani Subramanian, William Symonds, John G. McHutchison, Alessandra Mangia, Edward Gane, Masashi Mizokami, Stanislas Pol, Nezam Afdhal – 4 April 2015 – Patients with hepatitis C virus (HCV) infection and cirrhosis are underrepresented in clinical trials of interferon‐free regimens of direct‐acting antiviral agents, making it difficult to optimize therapy.

Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis type 2

Sharat Varma, Nicole Revencu, Xavier Stephenne, Isabelle Scheers, Françoise Smets, Ana Beleza‐Meireles, Raymond Reding, Tania Roskams, Etienne M. Sokal – 4 April 2015 – We investigated predictors of clinical evolution in progressive familial intrahepatic cholestasis type 2 patients and how they relate to bile salt export pump (BSEP) expression and its (re)targeting. Our retrospective study included 22 children with progressive familial intrahepatic cholestasis type 2.

Projections in donor organs available for liver transplantation in the United States: 2014‐2025

Neehar D. Parikh, David Hutton, Wesley Marrero, Kunal Sanghani, Yongcai Xu, Mariel Lavieri – 3 April 2015 – With the aging US population, demographic shifts, and obesity epidemic, there is potential for further exacerbation of the current liver donor shortage. We aimed to project the availability of liver grafts in the United States.

Pulmonary nodules in liver transplant candidates with hepatocellular carcinoma: Imaging characteristics and clinical outcomes

Christopher Lee, Lauren Ihde, Andrew Kim, Idoia Santos, Lea Matsuoka, Yong Cen, Melissa Wallman, Edward Grant – 2 April 2015 – No guidelines exist for the management of pulmonary nodules in patients with hepatocellular carcinoma (HCC) who are being evaluated for liver transplantation. The 172 patients with HCC who were listed for liver transplant at our institution received both pretransplant chest computed tomography (CT) and follow‐up CT.

Subscribe to